Navigation Links
QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System
Date:7/28/2009

uates the effect of artificial tears preserved with benzalkonium chloride (AT-BAK) on IOP response to L-PPDS; 22 patients are currently enrolled and enrollment is continuing. The second trial compares IOP and safety outcomes based on L-PPDS placement (upper or lower punctum); enrollment is complete with 30 patients, and follow-up is ongoing.

The Device Study (Punctal Plug Prototype Designs)

This study is an ongoing, device, open-label, multicenter study conducted to investigate the safety, tolerability, comfort, ease of handling and insertion/removal, and retention of punctal plug prototype designs, in healthy subjects. Subjects are fitted with a punctal plug in each eye and wear the devices for 24 hours, after which the plugs are removed and replaced. Subjects then wear the devices for up to 12 weeks. Enrollment is ongoing. The preliminary overall retention rate of 75% after eight weeks of follow-up is based on a baseline sample of 447 eyes from 239 subjects who were fitted with prototypes from one family of designs. Subject comfort ratings for this design family are high (mean of 97 on a scale of 0-100 at Week 8), and physician handling assessments indicate that the devices are easy to insert and remove. Interim analyses show that these designs have been well tolerated. The most frequently reported adverse events for subjects fit with this family of designs have been increased lacrimation, eye irritation, and device migration (2.1% for each event); conjunctival hyperemia (1.7%); and conjunctival edema and eye disorder (1.3% for each event). Interim analyses of all punctal plug prototype designs in 590 subjects show that the most frequently reported adverse events overall have been device migration (3.7%), conjunctival hyperemia (1.3%), and eye irritation (1.0%).

Prototype punctal plug designs continue to be refined and evaluated to meet our retention criteria and converge with the identification of a dose formulation to pr
'/>"/>

SOURCE QLT Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. QLT Announces Second Quarter Results for 2009
2. MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage
3. Grupo Casa Saba Announces Quarterly Earnings Report 2Q09
4. Image Sensors 2009 Announces Final Program and New Interactive Brochure
5. ULURU Inc. Announces Status of York Note Receivable
6. Danaher Corporation Announces Retirement of Executive Vice President Philip W. Knisely
7. Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales
8. Electronic Healthcare Network Announces Multi-State Expansion, Beginning in Buffalo, NY
9. Association of Gaming Equipment Manufacturers (AGEM) Announces $100,000 in Contributions to Organizations Working to Assist Problem Gamblers
10. American DG Energy Announces $3.5 Million Private Placement
11. Brookdale Announces Second Quarter 2009 Release and Earnings Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping tips ... the models at LunaDress.co.uk come with big discounts, up to 80 ... can turn out to be a most exciting memory and can ... bring surprise to a wedding. On the updated fashion blog, ladies ... for a big day . , Going out with friends to ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
(Date:12/24/2014)... Epigenetics finds applications in a large number ... discovery, developmental biology, and research for metabolic and genetic ... most widely used techniques for the discovery and development ... cancer is rapidly growing worldwide. In 2012, there were ... and 32.6 million people living with cancer (within five ...
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... Inc. (NYSE: MYL ),today announced that its subsidiary, ... and Drug Administration (FDA) for its,Abbreviated New Drug Application ... Zaleplon Capsules are the generic version of King Pharmaceuticals,Sonata(R) ... for,the 12 months ending March 31, 2008, according to ...
... news that DuPont,s Teflon chemicals likely,contaminate area residential wells. ... level., - Private residential well contamination with PFOA ... private drinking water wells and warnings,issued to residents in ... DEEPWATER, N.J., June 9 A coalition of,environmental ...
... ALEXANDRIA, Va., June 9 The National,Community ... of,Compounding Pharmacists (IACP) are collaborating to increase ... engage in compounding.,IACP has established a satellite ... their Director of Public Affairs, Sarah R. ...
... and Good Health this Father,s Day, Nearly 40 Million ... ... 9 Families sick and tired of Dad,s raucous,snoring, incessant allergic ... Snoring Center: a unique medical practice dedicated,exclusively to the evaluation and ...
... A new study demonstrates that microRNAs can modulate the ... may play a significant role in some human cancers. ... issue of the journal Cancer Cell, is likely to ... and leukemias. , MicroRNAs (miRNAs) are small noncoding pieces ...
... way solid tumors adapt the body,s machinery to bring ... these tumors stronger. , "In a sense, these therapies ... D.V.M., Ph.D., professor of radiation oncology at Duke University ... killing many if not most tumor cells, you are ...
Cached Medicine News:Health News:New Jersey Coalition Calls for Investigation of Private Wells to Protect Families from PFOA in Drinking Water 2Health News:New Jersey Coalition Calls for Investigation of Private Wells to Protect Families from PFOA in Drinking Water 3Health News:Pharmacist Associations Partner to Increase the Voice of Pharmacy 2Health News:Stop Dad's Sleepless Nights - and the Sniffles - With the Snoring Center 2Health News:Stop Dad's Sleepless Nights - and the Sniffles - With the Snoring Center 3Health News:MicroRNA controls expression of oncogenes 2Health News:Solid tumor cells not killed by radiation and chemotherapy become stronger 2
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... "US Self-monitoring Blood Glucose Market" report to ... This market insight focuses on the developments ... the United States . Reimbursement analysis and the ... analyses for more than 73 SMBG meters have been ...
(Date:12/22/2014)... 2014 Cyberonics, Inc. (NASDAQ: CYBX ), ... management of epilepsy, today announced it will participate in the ... January 14, 2015, in San Francisco . ... Executive Officer, will speak at 11:00 AM Pacific Time.  A ... clicking on the Investor Relations link on the Cyberonics home ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... (Nasdaq: NVAX ) a clinical-stage vaccine company, ... of Novavax will be presenting at the Stifel Nicolaus ... 17, 2010 at 10:20am local time at the Four ... company overview, outline its competitive position and characterize Novavax,s ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ... million shares of its common stock pursuant to an effective ... Inc. is the sole book-running manager of the offering and ... to purchase up to 1,245,000 additional shares. Halozyme intends to ...
Cached Medicine Technology:Halozyme Therapeutics Announces Public Offering of Common Stock 2Halozyme Therapeutics Announces Public Offering of Common Stock 3
...
Angled 45 Degrees to Right, 9.5mm blade, gently curved .5x .25mm blunt tips; Lower blade is 0.5mm longer; 14mm from mid screw to tip; (Available in left and right;) overall length 120mm; Stainless ...
16mm Slightly Curved sharp Tips; overall length 120mm; Stainless Steel...
16mm from Mid-Screw to Blunt Tips, Gently Curved Blades; overall length 120mm; Stainless Steel...
Medicine Products: